Wells Fargo raised the firm’s price target on Regeneron (REGN) to $615 from $580 and keeps an Equal Weight rating on the shares. The firm thinks the quarter was good and HD Eylea filler commentary was positive. This coupled with LAG3 readout getting pushed out makes the near-term story cleaner. However, Wells still struggles to see long-term buy case for the name.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $818 from $781 at Bernstein
- Regeneron price target raised to $865 from $815 at Guggenheim
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges